Leica Biosystems Expands Research Digital Pathology Portfolio with Launch of the compact Aperio CS5 Scanner
VISTA, California, January 27, 2026 – Leica Biosystems, a Danaher company and global leader in anatomic and digital pathology solutions, announces the launch of the Aperio CS5 scanner, a compact device designed to support digital transformation in research pathology. This latest innovation strengthens the Aperio Digital Pathology portfolio, offering researchers a powerful low to medium volume, high-quality whole slide imaging system.
The Aperio CS5 scanner delivers exceptional image quality in a compact footprint, making it ideal for research laboratories with limited space or those seeking an affordable entry point into digital pathology. Supporting both 1x3 inch and 2x3 inch slides in a tray-based system, the Aperio CS5 scanner provides flexibility, outputting images in SVS or DICOM format for seamless integration with existing workflows. The automatic or manual scanning modes enable full control to capture every slide with the proven quality of Aperio scanners.
“The Aperio CS5 scanner reflects our ongoing commitment to building a comprehensive digital pathology ecosystem,” said Naveen Chandra, Vice President and General Manager of Digital Pathology at Leica Biosystems. “As we continue to add to our portfolio, we’re giving customers more choice and the confidence that they can manage their entire workflow with a single, trusted partner. By offering accessible, scalable solutions across the research continuum, we’re helping scientists accelerate translational research and drive meaningful innovation.”
The Aperio CS5 scanner joins a robust suite of solutions within the Aperio Digital Pathology portfolio, which includes high-throughput instruments like the Aperio GT 450 scanner, mid-volume options such as the Aperio GT 180 scanner, and advanced software platforms like HALO Link and Aperio HALO AP for image management, and Aperio AI Store for computational analysis. Together, these solutions empower laboratories to transition from glass to digital with confidence, driving efficiency and unlocking new insights in pathology research.
Click here to learn more about the Aperio CS5 scanner and explore the full Aperio Digital Pathology portfolio.
Aperio CS5, Aperio GT 180, Aperio GT 450 and HALO Link are For Research Use Only. Not For Use In Diagnostic Procedures. In the USA, Aperio HALO AP is For Research Use Only. Not For Use In Diagnostic Procedures. Not all products shown may be available for use in your country.
About Leica Biosystems
Leica Biosystems is a cancer diagnostics company and a global leader in anatomic and digital pathology solutions. The company offers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. As the only company to own the full workflow from biopsy to diagnosis, Leica Biosystems is uniquely positioned to break down the barriers between each step. The company’s mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of its corporate culture. Leica Biosystems is proud to be a Danaher Corporation subsidiary.
